CD40 ligand deficiency causes functional defects of peripheral neutrophils that are improved by exogenous IFN-? - 06/11/18


Abstract |
Background |
Patients with X-linked hyper-IgM syndrome caused by CD40 ligand (CD40L) deficiency often present with episodic, cyclic, or chronic neutropenia, suggesting abnormal neutrophil development in the absence of CD40L-CD40 interaction. However, even when not neutropenic and despite immunoglobulin replacement therapy, CD40L-deficient patients are susceptible to life-threatening infections caused by opportunistic pathogens, suggesting impaired phagocyte function and the need for novel therapeutic approaches.
Objectives |
We sought to analyze whether peripheral neutrophils from CD40L-deficient patients display functional defects and to explore the in vitro effects of recombinant human IFN-γ (rhIFN-γ) on neutrophil function.
Methods |
We investigated the microbicidal activity, respiratory burst, and transcriptome profile of neutrophils from CD40L-deficient patients. In addition, we evaluated whether the lack of CD40L in mice also affects neutrophil function.
Results |
Neutrophils from CD40L-deficient patients exhibited defective respiratory burst and microbicidal activity, which were improved in vitro by rhIFN-γ but not soluble CD40L. Moreover, neutrophils from patients showed reduced CD16 protein expression and a dysregulated transcriptome suggestive of impaired differentiation. Similar to CD40L-deficient patients, CD40L knockout mice were found to have impaired neutrophil responses. In parallel, we demonstrated that soluble CD40L induces the promyelocytic cell line HL-60 to proliferate and mature by regulating the expression of genes of the same Gene Ontology categories (eg, cell differentiation) when compared with those dysregulated in peripheral blood neutrophils from CD40L-deficient patients.
Conclusion |
Our data suggest a nonredundant role of CD40L-CD40 interaction in neutrophil development and function that could be improved in vitro by rhIFN-γ, indicating a potential novel therapeutic application for this cytokine.
Le texte complet de cet article est disponible en PDF.Key words : Neutrophils, CD40 ligand, cell development, IFN-γ
Abbreviations used : APC, CD40L, CD62L, CFU, CGD, DEG, DMSO, FITC, fMLP, G-CSF, GPI, MFI, NET, PE, PEC, PMA, Q-VD-OPh, rhIFN-γ, RNAseq, ROS, sCD40L, TLR
Plan
Supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; grant 2012/50515-4 to O.C.-M. and grant 2012/51745-3 and 2016/22158-3 to A.C.-N.), the Jeffrey Modell Foundation (to A.C.-N.), and PENSI Institute and Ministério da Saúde do Brasil (PRONAS/PDC 2015 and 25000.077928/2015-06 to A.C.-N.). The animal studies were supported by a UAEU Program for Advanced Research grant (no. 31M193) from the Office of Research and Sponsored Projects, UAE University (to B.K.a.-R.). |
|
Disclosure of potential conflict of interest: T. R. Torgerson has consultant arrangements with Shire Pharmaceuticals, CSL Behring, UCB Pharmaceuticals, and ADMA Biologics and has received grants from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 5
P. 1571 - novembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?